Kazutaka Hosoya

Medical Staff

Kyoto University Hospital
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Brain metastases are frequent and often lethal complications of advanced cancers. Microglia, resident immune cells of the brain, are known to exert both anti-tumor and pro-tumor functions in late-stage metastases; however, their response during the initial outgrowth of metastatic lesions is not well characterized. Understanding how heterogeneous microglial subgroups are regulated in the developing tumor microenvironment could pave the way for therapeutic strategies to eliminate metastatic tumors at an early stage. In this study, we used a combination of in vivo fate map imaging, single-cell RNA sequencing, and a holographic photoconversion-based technique (Opto-omics) to track tumor fate and early microglial responses over time in the same animals during colonization of disseminated tumor cells. The microglial population was transcriptionally and morphologically heterogeneous, comprising both pro- and anti-tumor subsets. Genetic and pharmacological perturbations revealed that microglial phenotypes could be shifted by inhibiting TGF-β signaling or by deleting the tumor cell surface antigens CD24a and CD47. These findings reveal targetable plasticity in early-stage microglial responses to brain metastasis and suggest that harnessing pro-phagocytic microglial states may offer a therapeutic window before systemic immunosuppression becomes dominant.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

The BRAF V600E mutation is observed in 2% of the patients with lung adenocarcinoma (LUAD), and combination therapy targeting BRAF and mitogen‐activated protein kinase (MEK) is the standard treatment for this population. However, acquired resistance inevitably develops, which highlights the need for novel therapeutic strategies. In this study, we established a patient‐derived BRAF V600E‐mutated LUAD cell line, KTOR81, and investigated the potential of targeting the Yes‐associated protein 1 (YAP1)/transcriptional enhanced associate domain 1 (TEAD1) pathway in combination with BRAF inhibition. We observed that the novel TEAD1 inhibitor VT103 enhanced the efficacy of the BRAF inhibitor dabrafenib in KTOR81 cells and xenograft models. The combination of dabrafenib and VT103 downregulated the expression of the antiapoptotic protein survivin, which is transcriptionally regulated by the YAP1/TEAD1 complex, leading to increased apoptosis. Moreover, we used a LUAD tissue microarray to compare the staining patterns of YAP1, TEAD1, and survivin, and examined their association with prognosis. These analyses revealed a strong correlation between YAP1, TEAD1, and survivin expression in LUAD, suggesting the relevance of the YAP1/TEAD1‐survivin axis beyond BRAF V600E‐mutated cases. While no statistically significant association was observed between survivin expression and prognosis, when limited to driver oncogene‐positive patients, high survivin expression was suggested to be associated with poor prognosis. These findings provide preclinical evidence for the efficacy of combining TEAD1 inhibition with BRAF‐targeted therapy in BRAF V600E‐mutated LUAD and highlight the YAP1/TEAD1‐survivin axis as a potential therapeutic target especially in the driver oncogene‐positive LUAD patients.

Year:

2025

Year:

2025

Intratumor heterogeneity has been shown to be associated with treatment resistance in multiple cancers, including lung cancer. Elucidating intratumor heterogeneity is an issue that must be resolved to improve the prognosis of patients. Previous studies of intratumor heterogeneity have mainly involved collecting and analyzing cancer cells from patients, classifying subpopulation with different properties, and conducting comparative analysis. However, there are few studies focusing on the early phase of intratumor heterogeneity. We exposed alectinib to a commercially available ALK-positive lung cancer cell line (H2228) and established alectinib resistant cells (H2228-AR1S). H2228-AR1S was observed two cells with different appearances. In this intratumor heterogeneity model, flow cytometry (FACS) showed that the cell surface CD47 of the parent line was unimodal, whereas that of H2228-AR1S was bimodal, indicating that there were differences in the properties of migration and tumor formation between subpopulation having the CD47 high expression and subpopulation having CD47 low expression. Next, We exposed molecular targeted drugs to patient-derived lung cancer cell lines and evaluated the expression of cell surface markers using FACS. KTOR83-Dab, a cancer cell line derived from a BRAF-positive lung cancer patient that was exposed to dabrafenib for one month, showed bimodal EpCAM expression. The subpopulation of EpCAM low expression had high migration ability and showed reduced epithelial gene expression and increased mesenchymal gene expression, suggesting EMT (epithelial-mesenchymal transition). It was suggested that KTOR83-Dab is a patient-derived intratumor heterogeneity model. Furthermore, experiments are being conducted using these intratumor heterogeneity models to elucidate the mechanism of intratumor heterogeneity. H2228-AR1S is a intratumor heterogeneity model established from commercially available monoclonal cells, and single-cell analysis is performed to extract genes whose expression changes during the process of homogeneous cells becoming heterogeneous. KTOR83-Dab is a patient-derived lung cancer cell line and is therefore polyclonal. We will clone KTOR83-Dab and examine whether there are any cells that become heterogeneous when administered dabrafenib. In addition, based on the results of single-cell analysis of H2228-AR1s, we will also analyze genes involved in heterogeneity in KTOR83-Dab. Citation Format: Tomoko Funazo, Hiroaki Ozasa, Takahiro Tsuji, Yusuke Shima, Keiichiro Suminaga, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Toyohiro Hirai. Establishment of intratumor heterogeneity models using lung cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1260.

Year:

2025

Year:

2024

EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung cancer subsequently relapse. Some cancer cells survive the initial treatment with EGFR-TKIs, and this initial survival may be associated with subsequent recurrence. Therefore, we aimed to overcome the initial survival against EGFR-TKIs. We hypothesized that yes-associated protein 1 (YAP1) is involved in the initial survival against EGFR-TKIs, and we confirmed the combined effect of EGFR-TKIs and a YAP1–TEAD pathway inhibitor. The KTOR27 (EGFR kinase domain duplication) lung cancer cell lines established from a patient with EGFR mutation–positive lung cancer and commercially available PC-9 and HCC827 (EGFR exon 19 deletions) lung cancer cell lines were used. These cells were used to evaluate the in vitro and in vivo effects of VT104, a TEAD inhibitor. In addition, YAP1 involvement was investigated in pathologic specimens. YAP1 was activated by short-term EGFR-TKI treatment in EGFR mutation–positive lung cancer cells. In addition, inhibiting YAP1 function using siRNA increased the sensitivity to EGFR-TKIs. Combination therapy with VT104 and EGFR-TKIs showed better tumor-suppressive effects than EGFR-TKIs alone, in vitro and in vivo . Moreover, the combined effect of VT104 and EGFR-TKIs was observed regardless of the localization status of YAP1 before EGFR-TKI exposure. These results suggest that combination therapy with the TEAD inhibitor and EGFR-TKIs may improve the prognosis of patients with EGFR mutation–positive lung cancer.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Tomoko Funazo

Kyoto University Hospital

JAPAN
View details

Takashi Nomizo

Assistant Professor

Kyoto University Hospital

JAPAN
View details

Akihiko Yoshizawa

Kyoto University Hospital

JAPAN
View details

hironori yoshida

Kyoto University Hospital

JAPAN
View details

Masumi Hirabayashi

Associate Professor

National Institutes of Natural Sciences

JAPAN
View details

Hiroaki Ozasa

助教 / Assistant Professor

Kyoto University

JAPAN
View details

Takahiro Tsuji

Fred Hutch Cancer Center

UNITED STATES
View details

Hiroshi Date

Duke University Medical Center

UNITED STATES
View details

Toyohiro Hirai

Kyoto University

JAPAN
View details

Toshi Menju

Associate Professor

Kyoto University

JAPAN
View details

Daisuke Sugiyama

Senior Lecturer

Nagoya University

JAPAN
View details